Rebecca Weil
Corporate Officer/Principal bei OCULIS HOLDING AG
Profil
Rebecca Weil is currently the Chief Commercial Officer at Oculis Holding AG.
Prior to her current position, she held various roles including Director at Juvenile Diabetes Research Foundation (New York), Global Head-Marketing, Strategy & Pharmaceuticals at Bausch + Lomb Corp., and Head-Regional Franchise Asia, Middle East & Africa at Novartis AG.
From 2019 to 2023, she served as the Head-Global Marketing at Idorsia Ltd.
Before that, she was the Group Vice President & Head-Corporate Affairs at Shire Plc from 2018 to 2019.
Rebecca also worked as the Vice President & Head-Western Europe at Alcon AG.
She holds a doctorate degree from Massachusetts Institute of Technology and an undergraduate degree from Princeton University.
Aktive Positionen von Rebecca Weil
| Unternehmen | Position | Beginn |
|---|---|---|
| OCULIS HOLDING AG | Corporate Officer/Principal | 11.09.2023 |
Ehemalige bekannte Positionen von Rebecca Weil
| Unternehmen | Position | Ende |
|---|---|---|
| IDORSIA LTD | Vertrieb & Marketing | 01.08.2023 |
| SHIRE | Corporate Officer/Principal | 01.03.2019 |
| Juvenile Diabetes Research Foundation (New York) | Direktor/Vorstandsmitglied | - |
| BAUSCH + LOMB CORPORATION | Vertrieb & Marketing | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Ausbildung von Rebecca Weil
| Massachusetts Institute of Technology | Doctorate Degree |
| Princeton University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| OCULIS HOLDING AG | Health Technology |
| IDORSIA LTD | Health Technology |
| ALCON INC. | Health Technology |
| NOVARTIS AG | Health Technology |
| BAUSCH + LOMB CORPORATION | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
| Juvenile Diabetes Research Foundation (New York) |
